Go Pro
→ The options guide that actually starts at the beginning (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.82
-2.4%		$3.45
$1.03
▼
$8.48
$17.82M1.762.46 million shs7,690 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$1.46
+1.7%		$1.55
$0.58
▼
$2.50
$4.82M0.961.07 million shs19,633 shs
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$28.33
-0.8%		$32.62
$14.03
▼
$79.75
$18.98M244,151 shs93,278 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.29
$4.18
$1.11
▼
$19.65
$18.09M0.143,127 shs22 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-0.26%+9.83%+2.09%+25.32%+59.85%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-0.69%0.00%-8.33%+123.40%-36.44%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
0.00%0.00%-20.32%-15.45%+63.02%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+6.74%-11.14%+16.29%-76.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$3.82
-2.4%		$3.45
$1.03
▼
$8.48
$17.82M1.762.46 million shs7,690 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$1.46
+1.7%		$1.55
$0.58
▼
$2.50
$4.82M0.961.07 million shs19,633 shs
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$28.33
-0.8%		$32.62
$14.03
▼
$79.75
$18.98M244,151 shs93,278 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$4.29
$4.18
$1.11
▼
$19.65
$18.09M0.143,127 shs22 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-0.26%+9.83%+2.09%+25.32%+59.85%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-0.69%0.00%-8.33%+123.40%-36.44%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
0.00%0.00%-20.32%-15.45%+63.02%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00%+6.74%-11.14%+16.29%-76.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
1.00
SellN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.00
SellN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
1.00
SellN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INM, VYNE, ZIVO, and CYCN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/24/2026
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2.07M8.63N/AN/A$1.09 per share3.50
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.94M0.97N/AN/A$6.71 per share0.22
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$570K33.29N/AN/A$41.71 per share0.68
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K1,141.13N/AN/A($0.81) per share-5.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$3.53M-$1.66N/AN/AN/A-170.11%-87.96%-74.86%N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$8.16M-$2.89N/AN/AN/A-132.87%-80.85%-68.11%9/23/2026 (Estimated)
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$26.48M-$0.38N/AN/AN/A-4,726.21%-70.42%-63.46%N/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.71N/AN/AN/AN/AN/A-2,240.92%9/2/2026 (Estimated)

Latest INM, VYNE, ZIVO, and CYCN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.18-$3.51-$3.33-$3.51$0.20 million$0.10 million
8/4/2026Q2 2026
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$7.10-$0.41+$6.69-$0.41$1.50 millionN/A
5/15/2026Q1 2026
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$9.00-$4.00+$5.00-$0.08$0.20 million$0.09 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A

Latest INM, VYNE, ZIVO, and CYCN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/10/2026
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
special$19.007/22/20267/23/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
0.82
0.82
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A
3.12
3.12
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/A
20.86
20.86
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
83.78%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
34.30%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.85%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3.03%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
48.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
304.68 million3.08 millionNo Data
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
103.31 million3.29 millionNot Optionable
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
30670,000648,000Not Optionable
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.22 million2.91 millionNot Optionable

Recent News About These Companies

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023
March 18, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/03/zivo-stock-earnings-zivo-bioscience-for-q4-of-2023/?utm_source=marketbeat&utm_medium=referral
Harmony Biosciences Holdings
March 4, 2024  |  forbes.comhttps://www.forbes.com/companies/harmony-biosciences-holdings/
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM
Zivo Bioscience Inc (ZIVO) USD0.001
November 11, 2023  |  hl.co.ukhttps://www.hl.co.uk/shares/shares-search-results/z/zivo-bioscience-inc-usd1.001/costs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
SK hynix logo above a robotic arm placing memory chips on a wafer in a server data center.
Why SK hynix Could Be the Best AI Chip Stock to Buy Now
By Thomas Hughes | July 29, 2026
Interior hallway of an AMC movie theater with illuminated AMC logo, film posters, and showtime screens for numbered auditoriums.
Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
By Jeffrey Neal Johnson | August 12, 2026
Cyclerion Therapeutics stock logo

Cyclerion Therapeutics NASDAQ:CYCN

$3.82 -0.10 (-2.43%)
As of 11:17 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$1.46 +0.03 (+1.75%)
As of 11:17 AM Eastern
This is a fair market value price provided by Massive. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

VYNE Therapeutics stock logo

VYNE Therapeutics NASDAQ:VYNE

$28.32 -0.24 (-0.82%)
Closing price 07/27/2026
Extended Trading
$28.32 0.00 (0.00%)
As of 07/27/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$4.29 0.00 (0.00%)
As of 08/13/2026

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas